Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.81 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | RAD52 | P43351 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
| ▸ | DGKA | P23743 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 4/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3993048 | 0.97 | NAAA (0.86) | NAAAHTTRAD52NPSR1FAAH | |
| SCHEMBL12956536 | 0.97 | NAAA (0.86) | NAAAHTTRAD52NPSR1FAAH | |
| SCHEMBL14472850 | 0.97 | NAAA (0.86) | NAAAHTTRAD52NPSR1FAAH | |
| SCHEMBL2600809 | 0.94 | NAAA (0.73) | NAAAHTTRAD52NPSR1FAAH | |
| SCHEMBL20847 | 0.92 | NAAA (0.95) | NAAAHTTRAD52NPSR1FAAH | |
| SCHEMBL11409696 | 0.92 | NAAA (0.71) | NAAAHTTRAD52NPSR1FAAH | |
| Ethylene Glycol SCHEMBL50184 | 0.92 | NAAA (0.71) | NAAAHTTRAD52NPSR1FAAH | |
| SCHEMBL127979 | 0.90 | NAAA (1.00) | NAAAHTTRAD52NPSR1FAAH | |
| SCHEMBL1471551 | 0.90 | NAAA (1.00) | NAAAHTTRAD52NPSR1FAAH | |
| SCHEMBL21044673 | 0.90 | NAAA (1.00) | NAAAHTTRAD52NPSR1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 251 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240240106-A1 | 1,4-BUTANEDIOL MONO- OR DIESTERS FOR USE AS AROMA CHEMICALS | BASF SE (DE) | 2024-07-18 | — | — | US | claimed |
| EP-4347756-A1 | 1,4-BUTANEDIOL MONO- OR DIESTERS FOR USE AS AROMA CHEMICALS | BASF SE (DE) | 2024-04-10 | — | — | EP | claimed |
| CN-117396586-A | 1, 4-butanediol mono-or diesters as fragrance chemicals | 巴斯夫欧洲公司 | 2024-01-12 | — | — | CN | claimed |
| WO-2022248579-A1 | 1,4-BUTANEDIOL MONO- OR DIESTERS FOR USE AS AROMA CHEMICALS | BASF SE (DE) | 2022-12-01 | — | — | WO | claimed |
| CN-114874121-A | Method for preparing material containing monothiocarbonate group and product | 浙江大学 | 2022-08-09 | — | — | CN | claimed |
| CN-102171228-B | Method for producing mono-hydroxy-functionalized dialkylphosphinic acids, esters and salts by means of vinyl esters of carboxylic acids and use thereof | CLARIANT FINANCE BVI LTD | 2015-03-25 | — | — | CN | claimed |
| CN-102171227-B | Method for producing mono-carboxy-functionalized dialkylphosphinic acids, esters and salts using a vinyl ester of a carboxylic acid and the use thereof | CLARIANT INT LTD | 2014-11-12 | — | — | CN | claimed |
| CN-102171228-A | Method for producing mono-hydroxy-functionalized dialkylphosphinic acids, esters and salts by means of vinyl esters of carboxylic acids and use thereof | CLARIANT INT LTD | 2011-08-31 | — | — | CN | claimed |
| CN-102171227-A | Method for producing mono-carboxy-functionalized dialkylphosphinic acids, esters and salts using a vinyl ester of a carboxylic acid and the use thereof | CLARIANT INT LTD | 2011-08-31 | — | — | CN | claimed |
| US-4097453-A | STABILIZER IS 4-(PARA-TOLUENESULFONAMIDE) DIPHENYLAMINE | SOCIETA' ITALIANA RESINE S.I.R. S.P.A. (IT) | 1978-06-27 | — | — | US | claimed |
| EP-3076946-B1 | COMPOSITIONS COMPRISING ANTIOXIDANT, FLUID DISPENSERS, AND METHODS INVOLVING THE SAME | ALZET LLC (US) | 2026-01-07 | — | — | EP | disclosed |
| US-20250127776-A1 | ORAL PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2025-04-24 | — | — | US | disclosed |
| US-20250057835-A1 | ORAL PHARMACEUTICAL COMPOSITION CONTAINING HETEROCYCLIC COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2025-02-20 | — | — | US | disclosed |
| US-12097189-B1 | Pharmaceutical composition for modified release | ASTELLAS PHARMA INC. (JP) | 2024-09-24 | — | — | US | disclosed |
| US-20240293307-A1 | Compositions Comprising Antioxidant, Fluid Dispensers, and Methods Involving the Same | DURECT CORPORATION (US) | 2024-09-05 | — | — | US | disclosed |
| US-4111201-A | OSMOTIC SYSTEM FOR DELIVERING SELECTED BENEFICIAL AGENTS HAVING VARYING DEGREES OF SOLUBILITY | ALZA CORPORATION (US) | 1978-09-05 | — | — | US | disclosed |
| US-4111203-A | OSMOTIC SYSTEM WITH MEANS FOR IMPROVING DELIVERY KINETICS OF SYSTEM | ALZA CORPORATION (US) | 1978-09-05 | — | — | US | disclosed |
| US-4077407-A | POLYSACCHARIDES | ALZA CORPORATION (US) | 1978-03-07 | — | — | US | disclosed |
| US-4058122-A | Osmotic system with laminated wall formed of different materials | ALZA CORPORATION (US) | 1977-11-15 | — | — | US | disclosed |
| US-4008719-A | Osmotic system having laminar arrangement for programming delivery of active agent | ALZA CORPORATION (US) | 1977-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250127776-A1 | ORAL PHARMACEUTICAL COMPOSITION | LIPA, CYP2C19, PNLIP | NAAA 1821/4885HTT 1068/4885RAD52 4327/4885 |
| US-20250057835-A1 | ORAL PHARMACEUTICAL COMPOSITION CONTAINING HETEROCYCLIC COMPOUND | CYP2C19, CYP2C18, CYP3A7 | NAAA 1341/4885HTT 347/4885RAD52 4538/4885 |
| US-12097189-B1 | Pharmaceutical composition for modified release | SLC6A19, SLC6A15, GART | NAAA 608/4885HTT 646/4885RAD52 4769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.